Soon after last month’s end of her turbulent two-year run as CEO of X (formerly Twitter), Linda Yaccarino has landed another ...

GLP‑1 receptor agonists are widely recognized for aiding weight loss and controlling blood sugar, but access remains limited — especially for Medicare and Medicaid patients. That might change with a ...

Linda Yaccarino, the former CEO of the Elon Musk-owned social media platform X, has a new leadership gig in the weight loss space.

Dr. Tim Church predicted recently that GLP-1 agonists, GLP-1 /GIP agonists and similar prescription drugs will soon be as ...

The eMed Population Health digital health platform announced Tuesday that former X Chief Executive Officer Linda Yaccarino ...

Eris Lifesciences is using its growing insulin business to position itself as a serious contender in India’s fast-expanding ...

As Sky News research revealed thousands of severely obese patients are facing severely delayed treatment, here we look at the ...

For older adults with type 2 diabetes, glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with ...

Novo Nordisk stock was downgraded to Neutral from Buy by UBS analysts, who cited the threat posed by Eli Lilly as just one ...

Hims & Hers Health (HIMS) stock falls after reporting lower Q2 revenues. Analysts caution about near-term challenges, ...

A Massachusetts biotech working on a class of medicines called circular RNA therapeutics beat out companies from around the ...

As consumer interest in metabolic health, gut support and clean-label products accelerates, dietary fiber, like carob, ...